Novo Nordisk’s NovoLog has a list prices of $139.71 for FlexPen, $72.34 for 10 mL vial, and $134.37 for a PenFill Cartridge. Patients with commercial insurance whose coverage includes NovoLog may pay ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk (NVO) is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical companies next week. CEO Lars Jørgensen told reporters Thursday ...